Adaptimmune Reports Interim OS Data from SPEARHEAD-1 trial; Automatically Manufactured BNT211 Corroborates Initial Promising Efficacy Results in Solid tumors; Promising Initial Clinical Results of CT0180 in HCC; ASCO 2023 Analysis 3
Here is a brief preview of this blast: ASCO 2023 analysis 3: Adaptimmune, TCR2 Tx, BioNTech, and CARsgen Tx presented data on their cell therapy programs for solid tumors. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered: